Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and thrombosis
Mostafa Eltobgy,Ashley Zani,Adam D. Kenney,Shady Estfanous,Eunsoo Kim,Asmaa Badr,Cierra Carafice,Kylene Daily,Owen Whitham,Maciej Pietrzak,Amy Webb,Jeffrey Kawahara,Adrian C. Eddy,Parker Denz,Mijia Lu,KC Mahesh,Mark E. Peeples,Jianrong Li,Jian Zhu,Jianwen Que,Richard Robinson,Oscar Rosas Mejia,Rachael E. Rayner,Luanne Hall-Stoodley,Stephanie Seveau,Mikhail A. Gavrilin,Andrea Tedeschi,Santiago Partida-Sanchez,Frank Roberto,Emily A. Hemann,Eman Abdelrazik,Adriana Forero,Shahid M. Nimjee,Prosper Boyaka,Estelle Cormet-Boyaka,Jacob S. Yount,Amal O. Amer
DOI: https://doi.org/10.1101/2021.09.24.461743
2021-01-01
Abstract:AbstractSARS-CoV-2 is a worldwide health concern, and new treatment strategies are needed1. Targeting inflammatory innate immunity pathways holds therapeutic promise, but effective molecular targets remain elusive. Here, we show that human caspase-4 (CASP4), and its mouse homologue, caspase-11 (CASP11), are upregulated in SARS-CoV-2 infections, and thatCASP4expression correlates with severity of SARS-CoV-2 infection in humans. SARS-CoV-2-infectedCasp11-/-mice were protected from severe weight loss and lung pathology, including blood vessel damage, compared to wild-type (WT) and gasdermin-D knock out (Gsdmd-/-)mice. GSDMD is a downstream effector of CASP11 and CASP1. Notably, viral titers were similar in the three genotypes. Global transcriptomics of SARS-CoV-2-infected WT,Casp11-/-andGsdmd-/-lungs identified restrained expression of inflammatory molecules and altered neutrophil gene signatures inCasp11-/-mice. We confirmed that protein levels of inflammatory mediators IL-1β, IL6, and CXCL1, and neutrophil functions, were reduced inCasp11-/-lungs. Additionally,Casp11-/-lungs accumulated less von Willebrand factor, a marker for endothelial damage, but expressed more Kruppel-Like Factor 2, a transcription factor that maintains vascular integrity. Overall, our results demonstrate that CASP4/11, promotes detrimental SARS-CoV-2-associated inflammation and coagulopathy, largely independently of GSDMD, identifying CASP4/11 as a promising drug target for treatment and prevention of severe COVID-19.